Biopharmx Corp (NYSEAMERICAN:BPMX) has announced the receipt of patent protection for the novel gel delivery system, which ensures a bioavailability of active pharmaceutical ingredients, from The Patent and Trademark office of the US.
The topical composition consisting of tetracycline-class or minocycline class drugs as well as the method to make such compositions are included in the patent no. 9,918,998 for “Pharmaceutical Tetracycline Composition For Dermatological Use”. The treatment of dermatological infection or inflammation with the help of minocycline composition is also included in the granted patent.
The patent also covers BPX-04 formulation, which is used for the treatment of rosacea, and BPX-01, which is used to treat acne.
Biopharmx has earlier received three patents from the US Patent and Trademark office to safeguard its encapsulation delivery system. The patent no 9,901,586, which is received on February 27, 2018, is titled “Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers”.
According to Mrs. Anja Krammer, the cofounder and president said the latest patent is a recognition for its developmental activities of the topical tetracycline-class drug. She further said the patents protect the valuable intellectual properties for a longer duration. The R&D efforts of Biopharmx are well recognized and ensure a wealth of benefits for the shareholders as the company commercializes the products.
The physicians have been prescribing Oral minocycline since the 1970s. But the wide availability of Oral antibiotics is posing significant side effects ranging from diarrhea to nausea. The rise of antibiotic resistant bacteria is also causing a concern.
The companies have been spending millions of dollars for all these years to develop a soluble and stable minocycline formulation that reduces less resistance when compared to other tetracycline-class antibiotics. Biopharmx is the first company to achieve success in this field. It has developed a topical gel formulation of the minocycline to reach the targeted areas of your skin, where acne is likely to develop. The topical application of minocycline will help to treat skin related diseases.
After successfully completing the phase 2b trial of BPX-01 to cure acne, the drug is ready for phase 3 trial. BPX-04 has shown positive results for the treatment of rosacea. BPX-04 is ready for phase 2 trial.